211 related articles for article (PubMed ID: 32522059)
1. Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practice.
Wudhikarn K; Park JH
Leuk Lymphoma; 2020 Oct; 61(10):2324-2334. PubMed ID: 32522059
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions.
Schroeder BA; Jess J; Sankaran H; Shah NN
Curr Opin Hematol; 2022 Jul; 29(4):225-232. PubMed ID: 35787551
[TBL] [Abstract][Full Text] [Related]
3. Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies.
Kim SJ; Yoon SE; Kim WS
Ann Lab Med; 2024 May; 44(3):210-221. PubMed ID: 38205527
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
Yang Z; Wang Y
Chin Med J (Engl); 2023 Oct; 136(19):2285-2296. PubMed ID: 37358555
[TBL] [Abstract][Full Text] [Related]
5. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Ghilardi G; Fraietta JA; Gerson JN; Van Deerlin VM; Morrissette JJD; Caponetti GC; Paruzzo L; Harris JC; Chong EA; Susanibar Adaniya SP; Svoboda J; Nasta SD; Ugwuanyi OH; Landsburg DJ; Fardella E; Waxman AJ; Chong ER; Patel V; Pajarillo R; Kulikovskaya I; Lieberman DB; Cohen AD; Levine BL; Stadtmauer EA; Frey NV; Vogl DT; Hexner EO; Barta SK; Porter DL; Garfall AL; Schuster SJ; June CH; Ruella M
Nat Med; 2024 Apr; 30(4):984-989. PubMed ID: 38266761
[TBL] [Abstract][Full Text] [Related]
6. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
Khan AN; Asija S; Pendhari J; Purwar R
Eur J Haematol; 2024 Jan; 112(1):6-18. PubMed ID: 37545253
[TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy.
Shishido SN; Hart O; Jeong S; Moriarty A; Heeke D; Rossi J; Bot A; Kuhn P
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38350684
[TBL] [Abstract][Full Text] [Related]
8. FDA Investigating CAR-Related T-cell Malignancies.
Cancer Discov; 2024 Jan; 14(1):9-10. PubMed ID: 38032843
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies.
Ruella M; Korell F; Porazzi P; Maus MV
Nat Rev Drug Discov; 2023 Dec; 22(12):976-995. PubMed ID: 37907724
[TBL] [Abstract][Full Text] [Related]
10. Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies.
Angelos MG; Patel RP; Ruella M; Barta SK
Transplant Cell Ther; 2024 Feb; 30(2):171-186. PubMed ID: 37866783
[TBL] [Abstract][Full Text] [Related]
11. Engineering enhanced CAR T-cells for improved cancer therapy.
Milone MC; Xu J; Chen SJ; Collins MA; Zhou J; Powell DJ; Melenhorst JJ
Nat Cancer; 2021 Aug; 2(8):780-793. PubMed ID: 34485921
[TBL] [Abstract][Full Text] [Related]
12. Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies.
Zhang G; Deng L; Lu H; Zhang W
Int J Clin Pharm; 2024 Feb; 46(1):186-194. PubMed ID: 38087131
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma.
Rejeski K; Jain MD; Smith EL
Transplant Cell Ther; 2023 Jul; 29(7):418-428. PubMed ID: 37076102
[TBL] [Abstract][Full Text] [Related]
14. Prolonged haematologic toxicity in CAR-T-cell therapy: A review.
Liu Q; Hu T; Li H; Shen Y; Wu D; Ye B
J Cell Mol Med; 2023 Dec; 27(23):3662-3671. PubMed ID: 37702530
[TBL] [Abstract][Full Text] [Related]
15. A novel multicolor fluorescent spot assay for the functional assessment of chimeric antigen receptor (CAR) T-cell products.
Atanackovic D; Iraguha T; Omili D; Avila SV; Fan X; Kocoglu M; Gebru E; Baker JM; Dishanthan N; Dietze KA; Oluwafemi A; Hardy NM; Yared JA; Hankey K; Dahiya S; Rapoport AP; Luetkens T
Cytotherapy; 2024 Apr; 26(4):318-324. PubMed ID: 38340107
[TBL] [Abstract][Full Text] [Related]
16. Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies.
Huang Y; Qin Y; He Y; Qiu D; Zheng Y; Wei J; Zhang L; Yang DH; Li Y
Drug Resist Updat; 2024 May; 74():101082. PubMed ID: 38569225
[TBL] [Abstract][Full Text] [Related]
17. Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope?
Zhang PF; Xie D
Front Immunol; 2024; 15():1362133. PubMed ID: 38558812
[TBL] [Abstract][Full Text] [Related]
18. Improving CAR T cell therapy by optimizing critical quality attributes.
Reddy OL; Stroncek DF; Panch SR
Semin Hematol; 2020 Apr; 57(2):33-38. PubMed ID: 32892841
[TBL] [Abstract][Full Text] [Related]
19. Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer.
Tang L; Huang ZP; Mei H; Hu Y
Mil Med Res; 2023 Nov; 10(1):52. PubMed ID: 37941075
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation.
Khan AN; Chowdhury A; Karulkar A; Jaiswal AK; Banik A; Asija S; Purwar R
Front Immunol; 2022; 13():886546. PubMed ID: 35677038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
